Published in Clin Lymphoma Myeloma on March 01, 2009
Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study. Br J Cancer (2009) 1.17
Pathophysiology of Waldenström's macroglobulinemia. Haematologica (2010) 1.07
Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models. ISRN Hematol (2013) 0.79
Novel treatment options for Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk (2013) 0.77
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med (2012) 4.26
Incidence of and risk factors for nodding off at scientific sessions. CMAJ (2004) 2.97
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol (2010) 2.08
Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med (2015) 2.04
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol (2005) 1.91
Dangerous small B-cell clones. Blood (2006) 1.70
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood (2006) 1.51
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol (2012) 1.48
Digoxin prescribing for heart failure in elderly residents of long-term care facilities. Can J Cardiol (2005) 1.46
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood (2013) 1.44
Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia. Leuk Res (2009) 1.43
Characterization of genetic changes in MCL by interphase FISH on tissue sections. Leuk Lymphoma (2007) 1.40
Association between psychotropic drug use and heart failure therapy in elderly long-term care residents. J Am Geriatr Soc (2006) 1.38
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol (2009) 1.38
Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Sci (2005) 1.30
Nodding and napping in medical lectures: an instructive systematic review. CMAJ (2005) 1.30
Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol (2007) 1.26
Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood (2012) 1.23
Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther (2003) 1.22
A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res (2010) 1.21
Heart failure and cognitive impairment: challenges and opportunities. Clin Interv Aging (2007) 1.18
CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res (2007) 1.16
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol (2008) 1.15
Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy (2009) 1.14
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol (2012) 1.14
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood (2008) 1.09
Gene expression profiling and chromatin immunoprecipitation identify DBN1, SETMAR and HIG2 as direct targets of SOX11 in mantle cell lymphoma. PLoS One (2010) 1.08
Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma (2007) 1.07
Pathophysiology of Waldenström's macroglobulinemia. Haematologica (2010) 1.07
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma (2011) 1.03
Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica (2003) 1.03
Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica (2013) 1.03
Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood (2008) 1.03
Management of heart failure in Canadian long-term care facilities. Can J Cardiol (2004) 1.02
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res (2009) 1.00
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Clin Cancer Res (2008) 0.97
TCL1A expression delineates biological and clinical variability in B-cell lymphoma. Mod Pathol (2008) 0.97
Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol (2003) 0.96
Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol (2008) 0.95
T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab. Clin Cancer Res (2011) 0.95
Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett (2005) 0.94
CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. J Immunother (1991) (2001) 0.94
IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia. Haematologica (2009) 0.94
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia. Br J Haematol (2011) 0.92
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood (2014) 0.92
Portal vein thrombosis is a common complication following splenectomy in patients with malignant haematological diseases. Eur J Haematol (2006) 0.91
The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. Br J Haematol (2008) 0.91
Immunoglobulin M myeloma: evaluation of molecular features and cytokine expression. Clin Lymphoma (2005) 0.90
CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood (2008) 0.89
Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation. Int J Cancer (2008) 0.89
Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. Transplantation (2002) 0.88
Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk (2011) 0.88
Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma (2009) 0.87
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk (2012) 0.87
Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol (2011) 0.87
Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin Cancer Res (2009) 0.87
Kikuchi-Fujimoto disease (histiocytic necrotizing lymphadenitis): report of a case with other autoimmune manifestations. Proc (Bayl Univ Med Cent) (2007) 0.87
Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. Acta Oncol (2008) 0.86
High-resolution genomic screening in mantle cell lymphoma--specific changes correlate with genomic complexity, the proliferation signature and survival. Genes Chromosomes Cancer (2011) 0.86
Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood (2008) 0.85
High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia. Br J Haematol (2002) 0.85
Rapid intestinal transit as a primary cause of severe chronic diarrhea in patients with amyloidosis. Am J Gastroenterol (2003) 0.84
Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia. Med Oncol (2009) 0.84
CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. Clin Lymphoma (2005) 0.84
Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene. Clin Cancer Res (2009) 0.83
Novel agents in the treatment of Waldenström's macroglobulinemia. Clin Lymphoma Myeloma (2007) 0.83
Up-regulated estrogen receptor β2 in chronic lymphocytic leukemia. Leuk Lymphoma (2011) 0.83
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. Invest New Drugs (2007) 0.83
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells. Leuk Lymphoma (2011) 0.82
Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol (2011) 0.82
Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease. Med Oncol (2005) 0.82
ATM mutations in B-cell chronic lymphocytic leukemia. Haematologica (2004) 0.82
Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27. Clin Lymphoma Myeloma Leuk (2011) 0.81
Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. Br J Haematol (2009) 0.81
Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations. Semin Oncol (2003) 0.81
Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia. Clin Lymphoma Myeloma (2009) 0.81
Cell surface expression of CD25, CD54, and CD95 on B- and T-cells in chronic lymphocytic leukaemia in relation to trisomy 12, atypical morphology and clinical course. Eur J Haematol (2002) 0.81
Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. Br J Haematol (2008) 0.80
Biopsy-proven mantle cell lymphoma in brain parenchyma. Proc (Bayl Univ Med Cent) (2011) 0.80
Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study. Cancer Epidemiol (2011) 0.79
Long-term follow-up of liver transplantation for Budd-Chiari syndrome with antithrombotic therapy based on the etiology. Transplantation (2011) 0.79
Functional signatures identified in B-cell non-Hodgkin lymphoma profiles. Leuk Lymphoma (2009) 0.79
Urinary findings in renal light chain-derived amyloidosis and light chain deposition disease. Clin Lymphoma Myeloma (2009) 0.79
Reversibility of pamidronate-associated glomerulosclerosis. Proc (Bayl Univ Med Cent) (2007) 0.79
SOXC transcription factors in mantle cell lymphoma: the role of promoter methylation in SOX11 expression. Sci Rep (2013) 0.79
Comparison of serum immunofixation electrophoresis and free light chain assays in the detection of monoclonal gammopathies. Clin Lymphoma Myeloma Leuk (2010) 0.79